1.Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Byung Sup KIM ; Ho Jun SEOL ; Do Hyun NAM ; Chul Kee PARK ; Il Han KIM ; Tae Min KIM ; Jeong Hoon KIM ; Young Hyun CHO ; Sang Min YOON ; Jong Hee CHANG ; Seok Gu KANG ; Eui Hyun KIM ; Chang Ok SUH ; Tae Young JUNG ; Kyung Hwa LEE ; Chae Yong KIM ; In Ah KIM ; Chang Ki HONG ; Heon YOO ; Jin Hee KIM ; Shin Hyuk KANG ; Min Kyu KANG ; Eun Young KIM ; Sun Hwan KIM ; Dong Sup CHUNG ; Sun Chul HWANG ; Joon Ho SONG ; Sung Jin CHO ; Sun Il LEE ; Youn Soo LEE ; Kook Jin AHN ; Se Hoon KIM ; Do Hun LIM ; Ho Shin GWAK ; Se Hoon LEE ; Yong Kil HONG
Cancer Research and Treatment 2017;49(1):193-203
PURPOSE: The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. MATERIALS AND METHODS: A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively. RESULTS: After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients, respectively. The methylation status of O6-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period. CONCLUSION: Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.
Biopsy
;
Chemoradiotherapy*
;
Disease-Free Survival
;
Follow-Up Studies
;
Glioblastoma*
;
Humans
;
Korea*
;
Methylation
;
Radiotherapy
;
Retrospective Studies*
;
Survival Rate
2.Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
Seung Hyeun LEE ; Sue In CHOI ; Ji Sung LEE ; Chul Hwan KIM ; Won Jai JUNG ; Eun Joo LEE ; Kyung Hoon MIN ; Gyu Young HUR ; Seung Heon LEE ; Sung Yong LEE ; Je Hyeong KIM ; Sang Yeub LEE ; Chol SHIN ; Jae Jeong SHIM ; Kyung Ho KANG ; Kwang Ho IN
Cancer Research and Treatment 2017;49(1):141-149
PURPOSE: Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. MATERIALS AND METHODS: Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated. RESULTS: A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology. CONCLUSION: Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.
Biomarkers
;
Carcinoma, Non-Small-Cell Lung*
;
Disease-Free Survival
;
Drug Therapy*
;
Humans
;
Immunohistochemistry
;
Lung Neoplasms
;
Multivariate Analysis
;
Platinum
;
Prognosis
;
Reactive Oxygen Species*
;
Smoke
;
Smoking
3.Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Minkyu JUNG ; Jeeyun LEE ; Tae Min KIM ; Dae Ho LEE ; Jin Hyung KANG ; Sung Young OH ; Soo Jung LEE ; Sang Joon SHIN
Cancer Research and Treatment 2017;49(1):44-53
PURPOSE: Ipilimumab improves survival in advanced melanoma patients. However, the efficacy and safety of ipilimumab has not been evaluated in Asian melanoma patients with a high frequency of mucosal and acral melanoma subtypes. MATERIALS AND METHODS: Advanced melanoma patients treated with 3 mg/kg ipilimumab in a Korean multicenter named-patient program (NPP) were evaluated between September 2014 and July 2015. Baseline characteristics and blood parameters including neutrophil to lymphocyte ratio (NLR) were assessed, and outcome and adverse events were evaluated according to subtypes. RESULTS: A total of 104 advanced melanoma patients were treated. The primary sites were acral (31.7%), mucosal (26%), cutaneous (26%), uveal (9.6%), and unknown (6.7%). Sixty-eight patients (65.4%) experienced adverse events, and the most common toxicity was skin rash (22.1%), 10 patients (9.6%) experienced adverse events of grade 3 or higher. The median progression-free survival (PFS) was 2.73 months (95% confidence interval, 2.67 to 2.85), and there was no difference in PFS according to subtypes. Poor performance status, liver metastasis, and NLR (≥ 5) were independent poor prognostic factors by multivariate analysis. CONCLUSION: In the Korean NPP cohort, ipilimumab showed similar efficacy and tolerability compared to Western patients, regardless of subtypes. All subtypes should benefit from ipilimumab with consideration of performance status, liver metastasis, and NLR.
Asian Continental Ancestry Group
;
Biomarkers
;
Cohort Studies*
;
Disease-Free Survival
;
Exanthema
;
Humans
;
Immunotherapy
;
Liver
;
Lymphocytes
;
Melanoma*
;
Multivariate Analysis
;
Neoplasm Metastasis
;
Neutrophils
4.A Case of Endoscopically Treated Laryngopharyngitis Resulting from Clinostomum complanatum Infection.
Geum Soo LEE ; Sang Wook PARK ; Jin KIM ; Kang Seok SEO ; Kyoung Wan YOU ; Jae Hun CHUNG ; Hyeong Chul MOON ; Gun Young HONG
The Korean Journal of Gastroenterology 2017;69(3):177-180
A 46-year-old woman visited our hospital presenting throat pain and globus sensation. The symptoms occurred seven days after eating raw perch and mullet. An endoscopy under sedation showed a fluke―with an approximate length of 4.8 mm and width of 1.5 mm―on the left aryepiglottic fold, with active motility on the mucosa. It was extracted from the larynx using biopsy forceps and was identified as Clinostomum complanatum. To the best of our knowledge, this is the second reported case of human infection with Clinostomum complanatum diagnosed and treated by an endoscopy in Korea. Endoscopy is a useful tool in the diagnosis and treatment of patients at risk for parasitic infections complaining of throat pain.
Biopsy
;
Diagnosis
;
Eating
;
Endoscopy
;
Female
;
Foodborne Diseases
;
Humans
;
Korea
;
Larynx
;
Middle Aged
;
Mucous Membrane
;
Parasites
;
Perches
;
Pharynx
;
Sensation
;
Smegmamorpha
;
Surgical Instruments
5.Clinical and Epidemiologic Characteristics of Spreaders of Middle East Respiratory Syndrome Coronavirus during the 2015 Outbreak in Korea.
Chang Kyung KANG ; Kyoung Ho SONG ; Pyoeng Gyun CHOE ; Wan Beom PARK ; Ji Hwan BANG ; Eu Suk KIM ; Sang Won PARK ; Hong Bin KIM ; Nam Joong KIM ; Sung Il CHO ; Jong Koo LEE ; Myoung Don OH
Journal of Korean Medical Science 2017;32(5):744-749
Nosocomial transmission is an important characteristic of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. Risk factors for transmission of MERS-CoV in healthcare settings are not well defined. During the Korean outbreak in 2015, 186 patients had laboratory-confirmed MERS-CoV infection. Those suspected as a source of viral transmission were categorized into the spreader groups (super-spreader [n = 5] and usual-spreader [n = 10]) and compared to the non-spreader group (n = 171). Body temperature of ≥ 38.5°C (adjusted odds ratio [aOR], 5.54; 95% confidence interval [CI], 1.38–22.30; P = 0.016), pulmonary infiltration of ≥ 3 lung zones (aOR, 7.33; 95% CI, 1.93–27.79; P = 0.003), and a more nonisolated in-hospital days (aOR, 1.32 per 1 day; 95% CI, 1.09–1.60; P = 0.004) were significant risk factors in the spreader group. There was no different clinical factor between super-spreaders and usual-spreaders. Nonisolated in-hospital days was the only factor which tended to be higher in super-spreaders than usual-spreaders (Mean, 6.6 vs. 2.9 days; P = 0.061). Early active quarantine might help reducing the size of an outbreak.
Body Temperature
;
Coronavirus Infections*
;
Cross Infection
;
Delivery of Health Care
;
Disease Transmission, Infectious
;
Humans
;
Korea*
;
Lung
;
Middle East Respiratory Syndrome Coronavirus*
;
Middle East*
;
Odds Ratio
;
Quarantine
;
Risk Factors
6.Granulocyte Colony-Stimulating Factor-Induced Psoriasiform Dermatitis Improved by Narrowband Ultraviolet B.
Min Soo JANG ; Jong Bin PARK ; Joon Hee KIM ; Myeong Hyeon YANG ; Kang Hoon LEE ; Sang Hwa HAN ; Kee Suck SUH
Annals of Dermatology 2017;29(2):232-233
No abstract available.
Dermatitis*
;
Granulocytes*
7.Falsely Elevated Postvoid Residual Urine Volume in Uterine Myoma.
Tae Hee KIM ; Hyo Sang KIM ; Jung Wook PARK ; Oh Kyung LIM ; Ki Deok PARK ; Ju Kang LEE
Annals of Rehabilitation Medicine 2017;41(2):332-336
Precise measurement of postvoid residual (PVR) urine volume is a key factor in assessing patients with voiding dysfunction, including those with lower urinary tract problems. The safe and noninvasive ultrasound bladder scan is the preferred mode to measure PVR volume. However, this procedure has a false-positive rate up to 9%, in the presence of ovarian cysts, renal cysts, ascites, or uterine myoma with cystic degeneration. Until now, cystic lesions are known to cause false positivity in ultrasound bladder scanner. However, we encountered falsely-elevated PVR in two cases of non-cystic uterine myomas. We present these cases with detailed radiologic images and volume measurement data.
Ascites
;
Female
;
Humans
;
Leiomyoma*
;
Myoma
;
Ovarian Cysts
;
Ultrasonography
;
Urinary Bladder
;
Urinary Tract
8.Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study.
Jae Hyuk CHOI ; Jung Rae CHO ; Sang Min PARK ; Kunal Bikram SHAHA ; Floyd PIERRES ; Tserendavaa SUMIYA ; Kwang Jin CHUN ; Min Kyung KANG ; Seonghoon CHOI ; Namho LEE
Yonsei Medical Journal 2017;58(5):959-967
PURPOSE: The purpose of this study was to assess the potential benefit of a 5-hydroxytryptamine receptor antagonist, sarpogrelate-based triple antiplatelet therapy (TAPT) in comparison with dual antiplatelet therapy (DAPT) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). MATERIALS AND METHODS: 119 patients of STEMI were retrospectively assessed. All patients received aspirin and clopidogrel per standard of care. Among them, 53 patients received an additional loading dose of sarpogrelate and a maintenance dose for 6 months post-PCI (TAPT group), while others did not (DAPT group). RESULTS: The rates of complete ST-segment resolution at 30 minutes post-PCI and post-procedural thrombolysis in myocardial infarction flow were not significantly different between the two groups (52.8% vs. 48.5%, p=0.200; 92.5% vs. 89.4%, p=0.080). In addition, no significant differences were observed between the two groups with regard to 30-day and 12-month clinical outcomes (cardiac death, myocardial infarction, stent thrombosis, target vessel revascularization, and severe bleeding). Meanwhile, improvement in left ventricular (LV) systolic function was observed in the TAPT group [ΔLV ejection fraction (LVEF)=17.1±9.4%, p<0.001; Δglobal longitudinal strain (GLS)=−9.4±4.2% , p<0.001] at 6 months, whereas it was not in the DAPT group (ΔLVEF= 8.8±6.5%, p=0.090; ΔGLS=−4.6±3.4%, p=0.106). In multivariate analyses, TAPT was an independent predictor for LV functional recovery (odds ratio, 2.61; 95% confidence interval, 1.16–5.87; p=0.003). CONCLUSION: Sarpogrelate-based TAPT improved LV systolic function at 6 months in STEMI patients undergoing primary PCI.
Aspirin
;
Humans
;
Multivariate Analysis
;
Myocardial Infarction*
;
Percutaneous Coronary Intervention
;
Retrospective Studies*
;
Serotonin
;
Standard of Care
;
Stents
;
Thrombosis
;
Ventricular Function, Left
9.Novel glutathione-containing dry-yeast extracts inhibit eosinophilia and mucus overproduction in a murine model of asthma.
Yun Ho KIM ; Yean Jung CHOI ; Eun Jung LEE ; Min Kyung KANG ; Sin Hye PARK ; Dong Yeon KIM ; Hyeongjoo OH ; Sang Jae PARK ; Young Hee KANG
Nutrition Research and Practice 2017;11(6):461-469
BACKGROUND/OBSECTIVE: Airway inflammation by eosinophils, neutrophils and alveolar macrophages is a characteristic feature of asthma that leads to pathological subepithelial thickening and remodeling. Our previous study showed that oxidative stress in airways resulted in eosinophilia and epithelial apoptosis. The current study investigated whether glutathione-containing dry yeast extract (dry-YE) ameliorated eosinophilia, goblet cell hyperplasia and mucus overproduction. MATERIALS/METHOD: This study employed 2 µg/mL lipopolysaccharide (LPS)- or 20 ng/mL eotaxin-1-exposed human bronchial epithelial cells and ovalbumin (OVA)-challenged mice. Dry-YE employed in this study contained a significant amount of glutathione (140 mg in 100 g dry yeast). RESULTS: Human bronchial epithelial cell eotaxin-1 and mucin 5AC (MUC5AC) were markedly induced by the endotoxin LPS, which was dose-dependently attenuated by nontoxic dry-YE at 10-50 µg/mL. Moreover, dry-YE inhibited the MUC5AC induction enhanced by eotaxin-1, indicating that eotaxin-1-mediated eosinophilia may prompt the MUC5AC induction. Oral supplementation with 10-100 mg/kg dry-YE inhibited inflammatory cell accumulation in airway subepithelial regions with a reduction of lung tissue level of intracellular adhesion molecule-1. In addition, ≥ 50 mg/kg dry-YE diminished the lung tissue levels of eotaxin-1, eosinophil major basic protein and MUC5AC in OVA-exposed mice. Alcian blue/periodic acid schiff staining revealed that the dry-YE supplementation inhibited goblet cell hyperplasia and mucus overproduction in the trachea and bronchiolar airways of OVA-challenged mice. CONCLUSIONS: Oxidative stress may be involved in the induction of eotaxin-1 and MUC5AC by endotoxin episode and OVA challenge. Dry-YE effectively ameliorated oxidative stress-responsive epithelial eosinophilia and mucus-secreting goblet cell hyperplasia in cellular and murine models of asthma.
Animals
;
Apoptosis
;
Asthma*
;
Chemokine CCL11
;
Eosinophil Major Basic Protein
;
Eosinophilia*
;
Eosinophils
;
Epithelial Cells
;
Glutathione
;
Goblet Cells
;
Humans
;
Hyperplasia
;
Inflammation
;
Lung
;
Macrophages, Alveolar
;
Mice
;
Mucin 5AC
;
Mucins
;
Mucus*
;
Neutrophils
;
Ovalbumin
;
Ovum
;
Oxidative Stress
;
Trachea
;
Yeasts
10.Transient visual loss after lung surgery in a healthy patient: posterior reversible encephalopathy syndrome: A case report.
Tae Hoon KANG ; Sang Jun NA ; Tae Yun SUNG ; Choon Kyu CHO ; Hee Uk KWON ; Po Soon KANG
Anesthesia and Pain Medicine 2017;12(2):111-116
Postoperative visual loss is a rare complication of general anesthesia in patients undergoing lung surgery. If the visual complication is permanent, it can greatly affect the patient's quality of life. Posterior reversible encephalopathy syndrome (PRES) leads to visual disturbances and may be associated with hypertension, renal disease, eclampsia, and chemotherapy. Although PRES is usually reversible, delayed diagnosis and treatment can result in permanent damage. We herein report a case of PRES in a patient with no medical history. The patient's symptoms included somnolence, visual loss, and headache. He was treated with conservative therapy, and his vision abruptly recovered three days after surgery. He was discharged from the hospital without neurologic complications 13 days after surgery.
Anesthesia, General
;
Blindness
;
Delayed Diagnosis
;
Drug Therapy
;
Eclampsia
;
Female
;
Headache
;
Humans
;
Hypertension, Renal
;
Lung*
;
Posterior Leukoencephalopathy Syndrome*
;
Pregnancy
;
Quality of Life

Result Analysis
Print
Save
E-mail